ASTERIAS BIOTHERAPEUTICS, INC. AST Cash Flow

Asterias biotherapeutics, inc. (AST)

CashFlow / TTM

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
-20,296	-22,651	-24,397	-28,372	-31,169	-35,008	-31,439	-35,489	-31,049	-23,909	-22,367	-15,003	-13,424	-11,598	-10,783	-10,097	-24,336	-25,319	-23,851	-22,380	-5,573	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,459	0	0	0	0
Depreciation and amortization expense
-	-	-	-	-	-	-	-	-	-	-	564	517	525	531	530	534	453	340	221	95	0	0	0
Stock-based compensation
3,609	3,797	4,037	4,444	4,044	4,308	4,186	4,797	5,155	4,600	4,540	3,625	2,532	2,311	2,248	1,814	1,662	1,686	960	704	441	0	0	0
Amortization of intangible assets
2,686	2,686	2,686	2,686	2,686	2,686	2,686	2,686	2,685	2,686	2,686	2,686	4,692	4,723	4,735	4,789	2,837	2,134	1,450	725	0	0	0	0
Amortization of prepaid rent
-	-	-	-	-	-	-	-	-	-	-	85	85	85	84	85	0	0	0	-	-	-	-	0
Gain on sale of equipment, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	2	0	0	0
Deferred income tax benefit
-	-	-	-	-	-	-	-2,325	-5,121	-5,780	-6,570	-7,252	-6,587	-7,339	-7,610	-7,376	-8,456	-6,143	-4,630	-3,281	0	0	0	0
Common stock issued for services in lieu of cash
936	1,065	1,183	1,151	1,136	840	871	922	1,130	1,130	811	486	0	0	0	-	-	-	-	-	-	-	-	-
Gain from change in fair value of warrant liability
4,558	4,895	4,473	5,908	2,664	-1,838	-154	-3,108	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Distribution of Asterias warrants to shareholders other than BioTime, Inc.
-	-	0	-	-	-	-4,202	-5,285	-5,285	-3,125	-3,125	0	0	0	0	-	-	-	-	-	-	-	-	-
Gain from change in fair value of marketable equity securities
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Grant receivable
-	-	-	-	-	-	-	-	-	-	-	-118	0	0	0	118	0	0	0	-	-	-	-	0
Prepaid expenses and other current assets
-340	194	174	-13	-81	-332	507	887	1,180	1,021	711	680	625	470	204	182	214	156	263	423	222	0	0	0
Other assets
-488	-772	-979	-846	-597	-10	-10	-10	-11	90	92	95	0	0	0	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	329	182	-543	560	-24	-12	456	554	120	32	44	486	567	353	0	0	0
Accounts payable, accrued expenses and other current liabilities
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	1,863	469	1,625	464	584	894	270	373	199	-93	246	208	96	234	0	0	0
Deferred rent
-	0	41	-	-	68	77	87	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	0
Lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Deferred grant income
-	-	-291	-	-	-	-1,979	-328	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred grant income
-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-
Amount due to BioTime
-	-	-	-	-	-	-	-242	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Amount due to parent, BioTime, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-2,386	5,514	4,905	4,902	6,392	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-15,824	-	-10,204	-14,391	-10,843	-11,591	0	0	0	-	-	-	-	0
Net cash used in operating activities
-15,822	-17,438	-21,220	-24,437	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment
53	211	276	290	488	474	845	894	762	653	360	313	109	76	34	115	-153	871	1,343	1,247	1,600	0	0	0
Proceeds from the sale of marketable equity securities
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of security deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	307	307	300	55	54	0	0	0
Reimbursement of security deposit
-	-	0	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on construction in progress
-	-	-	-	-	-	-	-	-	-	3,989	4,279	4,049	2,737	515	219	0	0	0	-	-	-	-	-
Proceeds from sale of equipment and furniture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28	27	0	0	0
Net cash provided by investing activities
3,416	3,282	2,194	722	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
CASH FLOWS FROM FINANCING ACTIVITIES:
Financing costs for sale of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-
Reimbursement of security deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Net cash provided by/(used in) investing activities
-	-	-	-	-	-	-	-	-	-	-4,318	-	-4,159	-2,813	12,104	12,020	0	0	0	-	-	-	-	0
Proceeds from sale of common stock under at-the-market transactions
1,166	2,473	2,331	8,002	13,823	14,488	13,469	7,969	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing costs for at-the-market sales
36	76	82	238	492	520	478	328	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-
Proceeds from sale of common shares
-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	468	468	0	0	0	0	0	0
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	11,700	0	0	0	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-5	-2	16	18	116	113	2,021	2,026	1,939	1,939	36	29	0	0	0	-	-	-	-	-	-	-	-	0
Repayment of lease liability and capital lease obligation
-	0	507	-	-	659	443	427	316	5	101	1	0	0	0	-	-	-	-	-	-	-	-	-
Shares retired to pay for employees' taxes
160	160	160	0	34	66	83	168	232	200	183	98	0	0	0	-	-	-	-	-	-	-	-	-
Reimbursement from landlord on construction in progress
-	-	-	-	-	-	-	567	1,792	3,796	4,073	3,789	2,564	560	283	0	0	0	0	-	-	-	-	-
Payment to Geron in connection with acquisition of assets on October 1, 2013
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	228	0	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	20,289	-	21,983	19,979	5,834	476	0	0	0	-	-	-	-	0
Net cash provided by financing activities
10,310	11,598	11,486	17,181	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
NET DECREASE IN CASH AND CASH EQUIVALENTS
-	-	-7,540	-	-	-	10,491	8,617	5,281	5,833	147	8,107	7,620	2,775	7,095	905	4,933	12,795	325	2,171	91	0	0	0
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid during the period
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fully vested common stock and restricted stock units issued in payment for accrued employee bonuses
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of equipment and furniture, contributed by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	459	0	0	0	0
Construction in progress in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Landlord receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Available-for-sale BioTime securities contributed by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,985	0	0	0	0
Cancellation of indebtedness to BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,000	0	0	0	0
Transaction costs paid by BioTime, on behalf of the Company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Intangible assets acquired from Geron
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29,017	0	0	0	0
Adjustment to deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Investment in affiliates, contributed by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	416	0	0	0	0
Common stock and common stock warrants issued to BioTime and Geron in connection with acquisition and transfer of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74,098	0	0	0	0
Common stock issued upon investment by BioTime
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	0	0	0
Reduction of subscriptions receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-50	0	0	0	0
Common stock issued in exchange for non-cash consideration in connection with investment by officer
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	0